Abstract: Essential genes play an important role in the survival of an organism. It has been shown that cancer-associated essential genes are genes necessary for cancer cell proliferation, where these genes are potential therapeutic targets. Also, it was demonstrated that mutations of the cancer-associated essential genes give rise to the resistance of immunotherapy for patients with tumors. In the present study, we focus on studying the biological effects of the essential genes from a network perspective. We hypothesize that one can analyze a biological molecular network by decomposing it into both three-node and four-node digraphs (subgraphs). These network subgraphs encode the regulatory interaction information among the network’s genetic elements. In this study, the frequency of occurrence of the subgraph-associated essential genes in a molecular network was quantified by using the statistical parameter, odds ratio. Biological effects of subgraph-associated essential genes are discussed. In summary, the subgraph approach provides a systematic method for analyzing molecular networks and it can capture useful biological information for biomedical research.
Abstract: Today, the treatment of cancer, in a relatively short
period, with minimum adverse effects is a great concern for
oncologists. In this paper, based on a recently used mathematical
model for cancer, a guideline has been proposed for the amount
and duration of drug doses for cancer treatment by immunotherapy.
Dynamically speaking, the mathematical ordinary differential
equation (ODE) model of cancer has different equilibrium points;
one of them is unstable, which is called the no tumor equilibrium
point. In this paper, based on the number of tumor cells an
intelligent soft computing controller (a combination of fuzzy logic
controller and genetic algorithm), decides regarding the amount
and duration of drug doses, to eliminate the tumor cells and
stabilize the unstable point in a relatively short time. Two different
immunotherapy approaches; active and adoptive, have been studied
and presented. It is shown that the rate of decay of tumor cells is
faster and the doses of drug are lower in comparison with the result
of some other literatures. It is also shown that the period of
treatment and the doses of drug in adoptive immunotherapy are
significantly less than the active method. A recommendation to
oncologists has also been presented.